Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
- PMID: 14654627
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
Abstract
Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants. This statement provides revised recommendations for administering RSV prophylaxis to infants and children with congenital heart disease, for identifying infants with a history of preterm birth and chronic lung disease who are most likely to benefit from immunoprophylaxis, and for reducing the risk of RSV exposure and infection in high-risk children. On the basis of results of a recently completed clinical trial, prophylaxis with palivizumab is appropriate for infants and young children with hemodynamically significant congenital heart disease. RSV-IGIV should not be used in children with hemodynamically significant heart disease. Palivizumab is preferred for most high-risk infants and children because of ease of intramuscular administration. Monthly administration of palivizumab during the RSV season results in a 45% to 55% decrease in the rate of hospitalization attributable to RSV. Because of the large number of infants born after 32 to 35 weeks' gestation and because of the high cost, immunoprophylaxis should be considered for this category of preterm infants only if 2 or more risk factors are present. High-risk infants should not attend child care during the RSV season when feasible, and exposure to tobacco smoke should be eliminated.
Similar articles
-
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.Pediatrics. 2003 Dec;112(6 Pt 1):1447-52. doi: 10.1542/peds.112.6.1447. Pediatrics. 2003. PMID: 14654628
-
Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.Arch Pediatr Adolesc Med. 2000 Jan;154(1):55-61. Arch Pediatr Adolesc Med. 2000. PMID: 10632251
-
[Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].Klin Padiatr. 1999 Nov-Dec;211(6):450-5. doi: 10.1055/s-2008-1043832. Klin Padiatr. 1999. PMID: 10592925 Review. German.
-
Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?Ir Med J. 2000 Dec;93(9):284. Ir Med J. 2000. PMID: 11209917
-
Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.Adv Ther. 2011 Feb;28(2):110-25. doi: 10.1007/s12325-010-0101-y. Epub 2011 Feb 4. Adv Ther. 2011. PMID: 21318605 Review.
Cited by
-
Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study.Influenza Other Respir Viruses. 2022 Sep;16(5):906-915. doi: 10.1111/irv.12994. Epub 2022 Apr 26. Influenza Other Respir Viruses. 2022. PMID: 35474419 Free PMC article.
-
Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996-2013.Sci Rep. 2021 May 21;11(1):10684. doi: 10.1038/s41598-021-90107-8. Sci Rep. 2021. PMID: 34021214 Free PMC article.
-
Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?Int J Mol Sci. 2021 Apr 2;22(7):3703. doi: 10.3390/ijms22073703. Int J Mol Sci. 2021. PMID: 33918185 Free PMC article. Review.
-
Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.Hum Vaccin Immunother. 2021 May 4;17(5):1536-1545. doi: 10.1080/21645515.2020.1822134. Epub 2020 Oct 22. Hum Vaccin Immunother. 2021. PMID: 33090914 Free PMC article.
-
A COVID-19 human viral challenge model. Learning from experience.Influenza Other Respir Viruses. 2020 Nov;14(6):747-756. doi: 10.1111/irv.12797. Epub 2020 Aug 12. Influenza Other Respir Viruses. 2020. PMID: 32790065 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical